Last reviewed · How we verify
Anti TNF therapy including infliximab
Blocks tumor necrosis factor-alpha (TNF-alpha) by binding to it and preventing it from interacting with cell surface TNF receptors.
Blocks tumor necrosis factor-alpha (TNF-alpha) by binding to it and preventing it from interacting with cell surface TNF receptors. Used for Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis.
At a glance
| Generic name | Anti TNF therapy including infliximab |
|---|---|
| Sponsor | Janssen Biotech, Inc. |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Infliximab is a chimeric monoclonal antibody that selectively binds to human TNF-alpha, thereby inhibiting its interaction with cell surface TNF receptors. This action prevents the inflammatory cascade initiated by TNF-alpha and reduces inflammation in the body.
Approved indications
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ulcerative Colitis
- Crohn's Disease
Common side effects
- Injection site reaction
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
- Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease: A Randomized Trial (NA)
- Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors
- A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
- Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT (PHASE2)
- An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis
- An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA
- Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti TNF therapy including infliximab CI brief — competitive landscape report
- Anti TNF therapy including infliximab updates RSS · CI watch RSS
- Janssen Biotech, Inc. portfolio CI